D. Downey

发表

Antimycobacterial activity of nonantibiotics associated with the polypharmacy of cystic fibrosis (CF) against mycobacterium abscessus

J. Moore, B. Millar, Zara I Kirkwood, 2018, International journal of mycobacteriology.

Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.

J. Elborn, C. Colombo, P. Flume, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.

E. Mckone, J. Eustace, D. Bilton, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis Outcomes

A. Levy, M. Tunney, J. Elborn, 2015, Lung.

The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation

J. Elborn, M. Ennis, D. Downey, 2007, Pediatric pulmonology.

Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report

A. Jones, D. Downey, G. Wright, 2018, BMC Pulmonary Medicine.

Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures

L. Dupont, H. Janssens, S. van Koningsbruggen-Rietschel, 2021, Trials.

“Pathogen Eradication” and “Emerging Pathogens”: Difficult Definitions in Cystic Fibrosis

S. Funk, P. Gilligan, M. Tunney, 2018, Journal of Clinical Microbiology.

MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?

S. Bell, T. Kidd, C. Coulter, 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

TACKLING ANTIMICROBIAL RESISTANCE (AMR) - IN VITRO EFFECT OF SODIUM CHLORIDE ON ANTIBIOTIC SUSCEPTIBILITY IN CLINICAL PSEUDOMONAS AERUGINOSA ISOLATED FROM PATIENTS WITH CYSTIC FIBROSIS (CF)

F. Blasi, J. Moore, B. Cherie Millar, 2020, The Ulster medical journal.

Relative resistance index (RRI) – a scoring system for antibiotic resistance in Pseudomonas aeruginosa

A. Reid, J. Moore, B. Sutherland, 2017, British journal of biomedical science.

Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge.

P. Burgel, L. Dupont, I. Sermet-Gaudelus, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Tackling bias in clinical trials.

S. van Koningsbruggen-Rietschel, D. Downey, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Game changers: A new dawn for the treatment of cystic fibrosis

D. Downey, P. Doherty, 2015 .

Airway Inflammation and Host Responses in the Era of CFTR Modulators

D. McAuley, D. Doherty, C. Taggart, 2020, International journal of molecular sciences.

Theratyping in cystic fibrosis

D. Downey, K. Crawford, 2018, Current opinion in pulmonary medicine.

INCREASING BURDEN OF ANTIMICROBIAL RESISTANCE IN PSEUDOMONAS AERUGINOSA FROM ADULT PATIENTS WITH CYSTIC FIBROSIS (CF) IN NORTHERN IRELAND: THEN AND NOW

F. Blasi, J. Elborn, J. Moore, 2018, The Ulster medical journal.

Gram negative infections in cystic fibrosis: a review of preventative and treatment options

D. Downey, C. Addy, S. Caskey, 2020, Expert Opinion on Orphan Drugs.

Chronic lung disease in common variable immune deficiency (CVID): A pathophysiological role for microbial and non-B cell immune factors

M. Tunney, D. Edgar, G. Einarsson, 2017, Critical reviews in microbiology.

The Impact of Lung Proteases on Snake-Derived Antimicrobial Peptides

J. Dalton, C. Taggart, D. Downey, 2021, Biomolecules.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, Steve B Jones, K. Y. Wong, 2021, The Lancet.

SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network

L. Dupont, S. van Koningsbruggen-Rietschel, V. Bulteel, 2020, European Respiratory Journal.

Safety and Efficacy of Recombinant Alpha1‐Antitrypsin Therapy in Cystic Fibrosis

M. Keogan, J. Elborn, D. Bilton, 2006, Pediatric pulmonology.

Airway infection, systemic inflammation and lung clearance index in children and adults with cystic fibrosis

J. Bradley, M. Tunney, J. Elborn, 2018, European Respiratory Journal.

The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis

M. Dempster, M. Keogan, J. Elborn, 2007, Pediatric pulmonology.

Safety of sputum induction.

J. Elborn, M. Ennis, M. Kelly, 2000, Chest.

A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial

A. Mcguire, M. Clarke, J. Bradley, 2019, Trials.

Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.

N. Derichs, F. Vermeulen, J. Davies, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study

J. Mortensen, R. Fischer, S. Donaldson, 2020, ERJ Open Research.

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

C. Teneback, P. Sosnay, R. Klingsberg, 2019, The Lancet.

Closed circuit rebreathing to achieve inert gas wash-in for multiple breath wash-out

J. Elborn, N. Bell, A. Horsley, 2016, ERJ Open Research.

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis

M. Tunney, J. Elborn, D. Downey, 2017, European Respiratory Journal.

Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.

J. Elborn, J. Moore, B. Millar, 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis

M. Tunney, J. Elborn, J. Moore, 2016, ERJ Open Research.

The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: A UK survey of current practice

D. Bilton, J. Moore, D. Downey, 2019, Medical mycology.

Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis.

M. Keogan, J. Elborn, D. Bilton, 2006 .

Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age.

E. Picard, H. Mussaffi, H. Blau, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Diagnostic agreement among experts assessing adults presenting with possible cystic fibrosis: need for improvement and implications for patient care

N. McElvaney, B. Quon, A. Faro, 2022, ERJ Open Research.

Improved culture detection of Staphylococcus aureus from sputum of patients with cystic fibrosis (CF)

J. Moore, M. Ennis, J. Stirling, 2019, Journal of Clinical Pathology.

Airborne bacteria and fungi concentrations in airtight contemporary dwellings

Lukumon O. Oyedele, T. Sharpe, J. Moore, 2015 .

STAPHYLOCOCCUS AUREUS ENTEROTOXINS IN PEOPLE WITH CYSTIC FIBROSIS (CF)

J. Elborn, J. Moore, M. Ennis, 2020, The Ulster medical journal.

Building global development strategies for cf therapeutics during a transitional cftr modulator era.

C. Goss, P. Dřevínek, S. Donaldson, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Pathogen eradication ” and “ Emerging pathogens ” : 3 Difficult definitions in cystic fibrosis 4 5

S. Funk, P. Gilligan, M. Tunney, 2018 .

Effect of cystic fibrosis exacerbations on neutrophil function.

J. Elborn, M. Ennis, D. Downey, 2005, International immunopharmacology.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis

J. Moore, A. Reid, C. Taggart, 2020, European Respiratory Review.

The role of inflammation in cystic fibrosis pulmonary exacerbations

C. Taggart, D. Downey, C. Houston, 2020, Expert review of respiratory medicine.

Future therapies for cystic fibrosis

J. Davies, K. Southern, A. Smyth, 2023, Nature Communications.

P217 Cystic fibrosis with pancreatic insufficiency is associated with a high incidence of subfertility in women

E. Picard, H. Mussaffi, H. Blau, 2018, Journal of Cystic Fibrosis.

Current pregnancy outcomes in women with cystic fibrosis.

J. Trinder, D. Downey, C. Burden, 2012, European journal of obstetrics, gynecology, and reproductive biology.

Immunodeficiency in Bronchiectasis

J. Elborn, L. Devlin, D. Downey, 2018 .

Neutrophils in cystic fibrosis

J. Elborn, S. Bell, D. Downey, 2008, Thorax.

Improvements in symptomatic treatment strategies for cystic fibrosis: delivering CF care in the 21st century

J. Elborn, D. Downey, C. Addy, 2016 .

Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe

M. Mei-Zahav, P. Yiallouros, P. Dřevínek, 2021, ERJ Open Research.

Community analysis and co-occurrence patterns in airway microbial communities during health and disease

M. Tunney, J. Lipuma, J. Elborn, 2019, ERJ Open Research.

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.

R. Fischer, S. Mulrennan, D. Waltz, 2021, The Lancet. Respiratory medicine.

The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis

C. Taggart, D. Downey, S. Elborn, 2022, International journal of molecular sciences.

Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants

I. Sermet, D. Downey, L. Galietta, 2022, STAR Protocols.

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

G. Sawicki, R. Fischer, C. Owen, 2021, The Lancet. Respiratory medicine.

Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.

N. McElvaney, M. Tunney, J. Elborn, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Lung Clearance Index in Adults and Children With Cystic Fibrosis.

I. Bradbury, J. Bradley, M. Tunney, 2016, Chest.

A change in behaviour: getting the balance right for research and policy

C. Hughes, C. Ryan, D. Downey, 2016, International Journal of Clinical Pharmacy.

Who’s at The Door? – Surface Contamination of Door Frames in a Single-Bedded In-Patient Adult Cystic Fibrosis (CF) Unit

J. Moore, B. Millar, N. Misawa, 2020, The Ulster medical journal.

Survival dynamics of cystic fibrosis-related Gram-negative bacterial pathogens (Pseudomonas aeruginosa and Burkholderia cenocepacia) in Dead Sea and Atlantic Ocean waters.

J. Elborn, J. Moore, B. Millar, 2015, Journal of Water and Health.

Cardiovascular complications of cystic fibrosis

J. Elborn, D. Downey, 2020, Cardiovascular Complications of Respiratory Disorders.

Development of a core outcome set for trials investigating the long-term management of bronchiectasis

C. Hughes, C. Ryan, D. Downey, 2018, Chronic respiratory disease.

Competition between co-occurring invasive and native consumers switches between habitats

C. Hughes, C. Ryan, D. Downey, 2018 .

Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.

E. Springman, S. Aaron, V. Lucidi, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Clinical Research Fellow

J. Bradley, J. Elborn, L. Mcgarvey, 2019, The Ulster medical journal.

Highlights of the North American Cystic Fibrosis Conference 2008

T. Hilliard, D. Downey, H. McGowan, 2009, Journal of the Royal Society of Medicine.

193 In vitro synergistic effect of NaCl and antibiotics against P. aeruginosa from cystic fibrosis patients

F. Blasi, J. Elborn, J. Moore, 2017 .

Antimicrobial effect of dimethyl sulfoxide and N, N-Dimethylformamide on Mycobacterium abscessus: Implications for antimicrobial susceptibility testing

J. Moore, B. Millar, Zara I Kirkwood, 2018, International journal of mycobacteriology.

Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His

J. Elborn, A. Reid, N. Stein, 2017, ERJ Open Research.

Lung function and disease severity in cystic fibrosis patients heterozygous for p . Arg

J. Elborn, A. Reid, N. Stein, 2017 .

Lung function and disease severity in cystic fibrosis patients heterozygous for p . Arg 117

J. Elborn, A. Reid, N. Stein, 2017 .

Thoracic ultrasound for pleural effusion: delays and cost associated with departmental scanning.

D. Downey, T. Teare, K. Bateman, 2010, Respiratory medicine.

Pharmacists’ perspectives on monitoring adherence to treatment in Cystic Fibrosis

C. Ryan, D. Downey, K. Mooney, 2016, International Journal of Clinical Pharmacy.

Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study

J. Bradley, I. Bradbury, J. Bradley, 2017, BMJ Open Respiratory Research.

The relationship of outcome to Burkholderia cepacia, lung function and inflammatory markers in stable patients with cystic fibrosis

M. Dempster, M. Keogan, J. Elborn, 1999 .

Nitric oxide, iNOS, and inflammation in cystic fibrosis

J. Elborn, D. Downey, J. Elborn, 2000, The Journal of pathology.

Do veterinary antibiotics have efficacy against highly resistant Gram-negative pathogens from patients with cystic fibrosis?

J. Elborn, J. Moore, B. Millar, 2015, International journal of antimicrobial agents.

Genomic Analysis and Surveillance of Respiratory Syncytial Virus (RSV) Using Wastewater-Based Epidemiology (WBE)

Jennifer M. McKinley, J. McGrath, M. Shannon, 2023, medRxiv.

Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: a UK Survey.

J. Elborn, N. Jarad, T. Powell, 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Letter to the editor: Challenges and opportunities in the development of future CFTR modulator options for people with CF.

J. Taylor-Cousar, D. Downey, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?—Results of an in vitro study

B. Millar, J. Moore, D. Downey, 2018, Journal of clinical pharmacy and therapeutics.

Inflammatory biomarkers in urine of cystic fibrosis patients

M. Tunney, G. Parekh, P. Davis, 2014 .

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

K. C. Morris, Michele R. Shaw, Mohammed Salah Ibrahim, 2023, The Lancet.

The timing of hypertonic saline (HTS) and airway clearance techniques (ACT) in adults with Cystic Fibrosis (CF) during pulmonary exacerbation: Pilot data from a randomised crossover study. a

I. Bradbury, J. Bradley, M. Tunney, 2017 .

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis

M. Tunney, D. Downey, K. Tumelty, 2017, European Respiratory Journal.

Neutrophils in cystic fibrosis

D. Downey, J. Elborn, S. Bell, 2008, Thorax.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, K. Y. Wong, Ayesha Binte Ashfaq, 2021, Lancet.